CureVac (CVAC)

• Market cap: $644M
• 1 day: -4.01%
• 5 days: -8.89%
• 1 month: 15.26%
• 3 months: -11.15%
• 6 months: -11.96%
• Year to date: -31.50%
• 1 year: -27.53%
• 5 years: -94.87%
• 10 years: -94.87%

About: CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

Employees: 1,100

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

18% more call options, than puts

Call options by funds: $497K | Put options by funds: $421K

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

1.47% less ownership

Funds ownership: 6.44% [Q2] → 4.97% (-1.47%) [Q3]

6% less funds holding

Funds holding: 85 [Q2] → 80 (-5) [Q3]

18% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 28

28% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 18

33% less capital invested

Capital invested by funds: $49M [Q2] → $32.8M (-$16.2M) [Q3]